Eren Demirpolat

Eren Demirpolat


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
EDEren Demirpolat
Eren Demirpolat
Mükerrem Betül YererMükerrem Betül Yerer
Mükerrem Betül Yerer

1 July 2022 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
AGAyşe Günay
Ayşe Günay
EDEren Demirpolat
Eren Demirpolat
AÜALİ ÜNAL
ALİ ÜNAL
Mükerrem Betül YererMükerrem Betül Yerer
Mükerrem Betül Yerer

16 September 2022 in Medicine
Verified
Journal Article
Open access
AGAli Eray Günay
Ali Eray Günay
IKIbrahim Karaman
Ibrahim Karaman
AGAHMET GUNEY
AHMET GUNEY
KKKaraman Karaman
Karaman Karaman
EDEren Demirpolat
Eren Demirpolat
Mükerrem Betül YererMükerrem Betül Yerer
Mükerrem Betül Yerer
The aim of the present study was to perform clinical, biochemical, and radiological evaluation of the efficacy of mesenchymal stem cells derived from Wharton jelly (WJ) present within the human umbilical cord in the treatment of knee osteoarthritis. Between 2018 and 2019, 10 patients with knee osteoarthritis for whom the conservative treatment was not beneficial were included in the study. Patients were clinically, radiologically, and biochemically evaluated before treatment initiation. Thereafter, the patients were intra-articularly injected using a solution containing 1 × 108 WJ-derived MSCs. Evaluations were performed on day 21 (V1) and 42 (V2) and month 3 (V3), 6 (V4), and 12 (V5) after the procedure. At 1-year post-injection, visual analogue scale, Western Ontario and McMaster Universities Osteoarthritis Index, and Lequesne scores of patients were lower than those observed during the initial evaluation, whereas the mean 36-Item Short Form Health Survey score was higher. Cartilage thicknesses were found to be increased in all regions except in the medial femur, medial posterior femur, lateral posterior femur, and lateral posterior tibia regions in magnetic resonance imaging. A significant increase was observed in tumor necrosis factor-alpha, interleukin-1β, adiponectin, resistin, and interleukin-6 levels compared with pre-injection values. The leptin levels at 6-month and 1-year controls were lower than the pre-injection levels, and the decrease observed at 6 months was significant. In patients with knee osteoarthritis, intra-articular WJ-derived MSC injection causes significant pain reduction, satisfactory functional improvement, and increased patient satisfaction following a 1-year follow-up. These clinical improvements were supported by magnetic resonance images, along with changes in adiponectin and leptin levels in synovial fluid. Level of evidence: IV.

3 January 2020 in Acta Orthopaedica et Traumatologica Turcica
Verified
Journal Article
Open access
IKİbRahim Karaman
İbRahim Karaman
AGAli Eray Günay
Ali Eray Günay
Mükerrem Betül YererMükerrem Betül Yerer
Mükerrem Betül Yerer
EDEren Demirpolat
Eren Demirpolat
SDSerap Doğan
Serap Doğan
IKİbRahim Halil Kafadar
İbRahim Halil Kafadar
Objective: This study aimed to determine the effects of a natural diterpenoid, kirenol, on fracture healing in vivo in an experimental rat model of femur fracture and investigate its potential mechanism of action via the Wnt/β-catenin pathway. Methods: In this study, 64 male Wistar albino rats aged 5-7 weeks and weighing 261–348 g were randomly divided into 8 groups from A to L, with eight rats in each group. Standardized fractures were created in the right femurs of the rats and then fixed with an intramedullary Kirschner wire. Four experimental groups were administered 2 mg/kg/day kirenol (Groups C and G) and 4 mg/kg/day (Groups D and H) kirenol by oral gavage.Thereafter, the animals were sacrificed at two time points as follows: on the 10th day (Groups B, C and D) and on the 21st day (Groups F, G and H) after the surgery; fracture healing in each group was assessed radiologically and histopathologically. The Radiographic Union scale of tibia fracture scoring system was used in the radiological examination; callus volume and density were measured using computed tomography. In the histopathologic examination, the scoring system described by Huo et al. was used. Additionally, the mechanism of action was evaluated based on the analyses of protein expression of Wnt3a, LRP5, TCF-LEF1, β-catenin, and Runx-2 proteins using western blot analysis. Results: Among the animals sacrificed on the 10th day after the surgery, the highest histopathological and radiological scores were observed in Group D (p<0.05). Furthermore, the callus density (p0.05). The callus volume and density were the highest in Groups G and H, respectively, although the differences among groups were not significant. Conclusion: Kirenol may improve fracture healing in a dose-dependent manner with the early activation of the Wnt/β-catenin pathway and the activation of the Runx-2 pathway. Cite this article as: Karaman İ, Günay AE, Yerer MB, et al. Effect of kirenol on the interaction between the WNT/β-Catenin and RUNX2/TCF/LEF1 pathways in fracture healing in vivo. Acta Orthop Traumatol Turc 2020; 54(3): 320-9. DOI: 10.5152/j.aott.2020.03.529.

4 June 2024 in European Journal of Hospital Pharmacy
Verified
Journal Article
Closed access
PDF file
SDSema Dinçel
Sema Dinçel
EDEren Demirpolat
Eren Demirpolat
Objectives Vancomycin, a glycopeptide antibiotic has antibacterial activity against Gram-positive bacteria and is frequently used in the intensive care unit (ICU). Inappropriate therapeutic drug monitoring (TDM) of vancomycin is a common problem encountered in hospital daily practice. The aim of this study was to evaluate the appropriateness of vancomycin trough-guided TDM in patients treated in the ICU using a clinical pharmacy approach. Methods The study was conducted retrospectively in patients over 18 years old who had at least one vancomycin trough level and who had received intravenous (IV) vancomycin for ≥3 days between 1 November 2020 and 1 April 2022. The study included 137 patients. Patient demographics and relevant vancomycin TDM data were collected from medical records. The appropriateness of TDM was evaluated according to the criteria established based on the monitoring recommendations specified in consensus guidelines for therapeutic drug monitoring of vancomycin published by the American Society of Health-System Pharmacists (ASHP) in 2009 and 2020. Results Of a total of 238 vancomycin trough levels measured in patients, 32.4% were collected at an inappropriate time. When patients were evaluated in terms of TDM appropriateness according to vancomycin level ranges (20 µg/mL), we found the appropriate TDM was significantly higher in the therapeutic range (10–20 µg/mL) (p <0.001). Of the total 238 vancomycin trough concentrations taken from patients, 77 (32.4%) were measured at an inappropriate time. This caused dose withholding, wrong adjustments and therapy failure. The total TDM appropriateness of vancomycin was significantly higher in the therapeutic range defined as 10–20 µg/mL when evaluated based on ‘TDM appropriateness criteria’ (p <0.001). Conclusion Our study shows that appropriate vancomycin TDM increases the likelihood of achieving target trough concentrations. Involvement of clinical pharmacists in TDM management may prevent the development of adverse reactions by ensuring appropriate sampling time and appropriate interpretation of vancomycin levels.